Medicenna Therapeutics (MDNA) Announces Issuance of U.S. Patent Providing Added Intellectual Property Protection for its MDNA11 Program
Get Alerts MDNA Hot Sheet
Join SI Premium – FREE
Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that the US Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,117,943, titled “Superagonists and Antagonists of Interleukin-2.” The patent provides intellectual property (IP) protection for methods of treating a wide range of cancers specified in the claims with interleukin-2 (IL-2) variants such as MDNA11, which is Medicenna’s selective, long-acting and novel IL-2 super-agonist. The patent’s term extends into at least 2032, without accounting for any potential extensions.
“This patent adds to our robust IP portfolio around MDNA11 and other IL-2 Superkines, which is a core component of our value creation strategy,” said Fahar Merchant, PhD, President and CEO of Medicenna. “The granted claims specifically focus on our platform based on enhanced affinity for the IL-2 receptor beta, which is a key point of differentiation between MDNA11 and competing ‘pegylated not-alpha’ IL-2 agents currently in the clinic. We are pleased to see this new patent granted and look forward to the progression of our recently initiated Phase 1/2 ABILITY Study of MDNA11, which treated its first patient last week.”
Medicenna holds an exclusive world-wide license to U.S. Patent No. 11,117,943, through its previously announced agreement with Stanford University, along with additional issued and filed patents in US, Europe, Japan, China, Canada and India which provide foundational composition-type protection for its IL-2 Superkine platform, including MDNA11.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) Announces KRYSTAL-12 Trial of KRAZATI Met Primary Endpoint
- National Storage Affiliates Trust (NSA) Appoints Melissa Cameron as Chief Marketing Officer
- Bristol-Myers Squibb (BMY) Provides Update on the First Phase 3 YELLOWSTONE Trial of Oral Zeposia
Create E-mail Alert Related Categories
Corporate News, LitigationRelated Entities
Stanford, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!